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Abstract
Background: Cell survival mediated by integrin engagement has been implicated in cell adhesion-mediated drug resistance.
We have recently demonstrated that the activation of glycogen synthase kinase 3 b (GSK3b) is a new pathway supporting
the chemoresistance of leukemic cells adhered to fibronectin.
Methodology and Principal Findings: We show here that in conditions of serum starvation, the fibronectin receptor a5b1
integrin, but not a4b1, induced activation of GSK3b through Ser-9 dephosphorylation in adherent U937 cells. The GSK3b-
dependent survival pathway occurred in adherent leukemic cells from patients but not in the HL-60 and KG1 cell lines. In
adhesion, activated GSK3b was found in the cytosol/plasma membrane compartment and was co-immunoprecipitated with
a5 integrin, the phosphatase PP2A and the scaffolding protein RACK1. PP2A and its regulatory subunit B’ regulated the Ser-9
phosphorylation of GSK3b. In adherent leukemic cells, a5b1 integrin but not a4b1 upregulated the resistance to TNFa-
induced apoptosis. Both extrinsic and intrinsic apoptotic pathways were under the control of a5b1 and GSK3b.
Conclusions and Significance: Our data show that, upon serum starvation, a5b1 integrin engagement could regulate
specific pro-survival functions through the activation of GSK3b.
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Introduction
The glycogen synthase kinase 3b (GSK3b) is a serine/threonine
protein kinase that is involved in many physiological processes,
playing important roles in glucose metabolism, cell cycle division,
cell adhesion and apoptosis. Deregulation of GSK3b activity is
implicated in the pathogenesis of neurodegenerative and meta-
bolic disorders, but also in cancer [1]. GSK3b is constitutively
active under its Tyr-216 phosphorylated form and regulates many
intracellular signaling pathways. At the post-translational level, the
function of GSK3b is inhibited through phosphorylation of the Ser
9 residue by other protein kinases, including Akt, in response to
insulin and growth factors [2].
Following integrin engagement, both inhibition and activation
of GSK3b have been described. GSK-3b is inhibited by Ser-9
phosphorylation by the ILK/Akt and Cdc42/PKCf pathways to
promote integrin-mediated cell proliferation or migration, respec-
tively [3,4]. Conversely, cell adhesion to a 3D collagen matrix
through a2b1 engagement promotes activation of GSK3b as well
as protein phosphatase 2A (PP2A) [5]. PP2A has been previously
shown to reactivate GSK3b through dephosphorylation of Ser-9
[6,7]. However, no role has been ascribed to the activated form of
GSK3b downstream of integrin engagement.
We have previously shown that GSK3b activation promotes the
chemoresistance of adherent leukemic cells on fibronectin or on
osteoblasts under serum starvation [8]. The endosteal niche
supports chemoresistant leukemic stem cells [9] and is thought to
be rich in fibronectin and hypoxic [10]. Adhesion of serum-starved
leukemic cells to fibronectin through a4b1 and a5b1 engagement
allows both Ser-9 dephosphorylation of GSK3b and NF-kB
activation [8]. Others and we have demonstrated that GSK3b can
upregulate cell survival through epigenetic and IkB-independent
control of NF-kB activity [8,11–14]. Strikingly, the anti-apoptotic
role of GSK3b has been demonstrated in different tumors and
may involve resistance to death receptor-induced apoptosis [15–
20]. Recently, GSK3b was found associated with DDX3 and c-
IAP-1 in a death antagonizing signaling complex at death
receptors and the resistance to apoptosis was overcome by
GSK3 inhibitors [21]. A mitochondrial-mediated cell death was
also found regulated by GSK3 [22].
Adhesion to fibronectin through a4b1 and a5b1 engagement
supports cell adhesion-mediated drug resistance (CAM-DR) of
many tumors [23]. Different specific fibronectin domains are
bound by a4b1 and a5b1 integrins and could each induce opposing
effects on cell survival and proliferation [24]. The aim of our study
was thus to determine the respective roles of a4b1 and a5b1 in
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results demonstrate that a5b1 but not a4b1 regulates a signaling
pathway leading to GSK3b activation and cell survival.
Materials and Methods
Antibodies and pharmacological inhibitors
Monoclonal antibodies against GSK3b, flotillin and RACK1
were from BD Transduction Laboratories. Monoclonal antibodies
GSK3a/b, actin and integrin subunits (a5, P1D6; a4, P4G9) were
purchased from Upstate or Biosource International (Camarillo,
CA, USA), Sigma and Dako (Carpinteria, CA, USA), respectively.
Monoclonal antibodies against a5 subunit (clone JBS5), Akt and
caspases were from Chemicon International, Santa Cruz Biotech-
nology (Santa Cruz, CA, USA) and Cell Signaling technology
(Beverly, MA, USA), respectively. Polyclonal antibodies directed
against PP2A-A (catalytic subunit of PP2A) and PP2A tyrosine
phosphorylated at position 307 were from Santa Cruz Biotech-
nology, and those against integrin subunits (a4 and a5) came from
Chemicon International. Polyclonal antibodies directed against
PP2A-B’ (regulatory subunit of PP2A), cytochrome C, GSK3a/
bserine phosphorylated at position 21/9 and Akt threonine
phosphorylated at position 308 were from Cell Signaling
Technology. Polyclonal antibody against p85 was from Upstate.
Horseradish-peroxydase-conjugated secondary antibodies against
mouse, rabbit or goat were from Cell Signalling Technology.
Okadaic acid, a PP2A inhibitor, and the GSK3b inhibitor
SB216763 were from Sigma. For Western blotting after immuno-
precipitation, GSK3b (monoclonal from BD Transduction
Laboratories) and P(ser9)GSK3b (polyclonal from Abcam) anti-
bodies have been biotynylated in our laboratory.
Cells and cell culture
The human leukemic cell lines U937, HL-60 and KG1 were
purchased from the German Collection of Microorganisms and
Cell Cultures (Braunschweig, Germany). U937 and HL-60 cells
were grown at 37uCi n5 %C O 2 in RPMI-1640, containing 10%
FCS, 50 mg/ml penicillin, and 50 mg/ml streptomycin. KG1 cells
were grown in the same conditions in IMDM 20% FCS. Bone
marrow leukemic cells from patients with acute myeloid leukemia
(AML) were obtained upon informed consent and processed for
their conservation as described previously [8]. Leukemic samples
were characterized at the Hematology Department of Toulouse
University Hospital (France), classified along French American
British (FAB) classification (FAB0: undifferentiated AML; FAB1:
myeloblastic AML; FAB2: myeloblastic with differentiation AML;
FAB4: myelomonocytic AML; FAB5: monocytic AML). The
samples contained more than 80% leukemic blasts after process-
ing. After thawing, viable cells from patients were checked by blue
trypan labelling, resuspended in IMDM, then washed once and
quickly used for in vitro experiments.
Transfection of siRNA
U937 cells were transfected using the Amaxa nucleofection
technology (Amaxa, Koeln, Germany), as indicated in [8]. 6610
6
U937 cells in 100 ml solution V were mixed with 200 nM siRNA
GSK3b, 100 nM siRNA PP2A-B’ or with 100–200 nM non-
targeting siRNA (Dharmacon Inc., Lafayette, CO, USA). For
siRNA integrin, two sources have been used to target a4 and a5
subunits: Ambion (30 nM) and Qiagen (50 nM). Cells were
immediately nucleofected with an Amaxa Nucleofector apparatus
(Amaxa, program V01), then transferred into wells containing
37uC prewarmed culture medium in six-well plates. After
transfection, cells were cultured from 24 to 96 h before analysing
by Western blotting or FACS. Decrease of GSK3b and a4 integrin
subunit was maximal at 48 h and maintained at 72 h whereas
decrease of PP2A-B’ and a5 integrin subunit was maximal at 72 h.
Therefore, survival tests and Western blot analysis were performed
at 72 h post-nucleofection.
Western blotting
For Western blotting, 0.5–1610
6 cells washed in Phosphate
Buffer Saline (PBS) were denatured in Laemmli sample buffer.
After sonication for 10 seconds and boiling for 10 min, proteins
were resolved on polyacrylamide SDS gels (SDS–PAGE) and
transferred to nitrocellulose (membrane Hybond-C super, Milli-
pore). The membrane was blocked for 1 h at room temperature in
Tris-buffered saline (TBS) containing 5% fat-free milk and then
was probed overnight at 4uC with the appropriate monoclonal or
polyclonal antibodies in TBS, 0.1% Tween, 3% fat-free milk and
3% Bovine Serum Albumin (BSA, Euromedex). After incubation
for 1 h at room temperature with either anti-mouse or anti-rabbit
IgG antibody coupled to horseradish peroxidase, or streptavidin-
HRP, detection was achieved using a chemiluminescent substrate
(SuperSignal, Amersham Pharmacia Biotech).
Survival and adhesion assays
We have previously set-up a protocol to study the survival
pathway in leukemic cells strictly dependent on the integrin
engagement without extrinsic growth factors that should not be
found in the leukemic niche [8]. Thus, adhesion assays and
treatments of cells were performed during 5 h of serum starvation
followed by re-addition of serum to discard serum deprivation-
linked cytotoxicity, and cell viability was measured at 24 h. Since
adhesion under serum-starved conditions was required to trigger
GSK3b activation downstream of integrin engagement (prelimi-
nary experiments not shown), we have thus measured the
differential of GSK3b-linked cell survival between suspension
and adhesion upon serum-starved conditions. Half of a 96 well
microtiter plate (MaxiSorp Immuno Plate, Nunc, Denmark) was
coated overnight at 4uC with 40 mg/ml of human fibronectin
(Roche Molecular Biochemicals, Mannheim, Germany) in a final
volume of 50 ml in PBS, and subsequently incubated with 1% fatty
acid-free BSA in PBS to block non specific adhesion sites, 1 h at
room temperature. Leukemic cells were diluted to 0.3610
6/ml,
left overnight (cell lines) or immediately processed after thawing
(AML cells, protocol described below) and then serum-starved for
1 h, incubated or not with okadaic acid (100 nM) or SB216763
(10 mM). Then, cells were allowed to adhere on fibronectin-coated
microtiter 96 well plates (0.8610
5 cells/well) for 1 h at 37uCo r
maintained in suspension. Where shown, leukemic cells in
suspension or adhesion were treated with 10 ng/ml TNFa for
4 hours after which cells were washed and incubated in serum-
containing medium for 24 h at 37uC. Cell viability was then
quantified by methyl thiazolyl tetrazolium (MTT) assay (Sigma).
In some experiments, leukemic cells were allowed to adhere on a
surface coated with a4-o ra5-specific antibodies (clones P4G9,
P1D6, JBS5: 1, 0.1 mg/ml and 0.2 mg/ml for optimal adhesion,
respectively) as previously described in [8]. Assays were performed
in triplicate. For the quantification of cell adhesion, adherent cells
were washed in PBS, fixed with a Karnovsky solution and stained
with 0.1% crystal violet solution.
For the apoptosis assay, 1610
6 U937 cells treated with control,
GSK3b or integrin siRNAs were processed as described for the
survival assay and at 5 h of incubation were washed with 1x PBS
and then incubated 15 min at room temperature with a FITC-
labeled Annexin-V/propidium iodide solution (Sigma). These cells
were directly analysed in a FACScan (Becton Dickinson) with a
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PLoS ONE | www.plosone.org 2 March 2010 | Volume 5 | Issue 3 | e9807Figure 1. Implication of GSK3b, a4b1 and a5b1 integrins in the survival of adherent leukemic cells. A- 72 hours after nucleofection of
siRNA directed to GSK3b, a4 or a5 subunits, U937 were serum starved, adhered to fibronectin, and then underwent a survival assay 24 hours later with
MTT (left panel, n=6, mean 6 S.E.M.) or 5 hours later with annexin-PI labeling (right panel, n=4, mean 6 S.E.M.). In MTT assays, data are expressed as
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PLoS ONE | www.plosone.org 3 March 2010 | Volume 5 | Issue 3 | e9807sample size of at least 10,000 cells gated on the basis of forward
and side scatter. Storing and processing of data was accomplished
using FACScan software and allowed the determination of the
percentages of living, apoptotic and necrotic cells. Following the
protocol described above including adhesion and TNF treatment
upon serum starvation, the apoptotic effectors (caspases, cyto-
chrome C) were detected by Western blot at 4 h after re-addition
of serum.
In our experiments, we have only used samples from AML
patients that did not display cell death after thawing over 10% as
checked by blue trypan labeling. After thawing, cells were cultured
in IMDM without serum for 2 h and then allowed to adhere on
fibronectin. At the end of 4 h adhesion, culture medium was
supplemented by SVF to maintain the cells until 24 h. Cell
survival of AML blasts from patients was measured at 24 h by
MTT labeling. Measurement of apoptosis in AML blasts treated
or not by TNFa was realized by FACS using labeling by APO2.7
(APO2.7–PC5 monoclonal antibody from Immunotech, Marseille,
France), a mitochondrial membrane protein expressed during the
early stages of apoptosis in relation to the release of cytochrome C
outside the mitochondria. APO2.7 labeling has been chosen since
in our control apoptotic assays performed with daunorubicin we
detected interference with the Annexin-V fluorescence (not
shown). In our experimental conditions, spontaneous death after
thawing was maximally 20% at 24 h (not shown).
Subcellular fractionation and a5 immunoprecipitation
Culture dishes were coated overnight at 4uC with 40 mg/ml of
human fibronectin in a final volume of 10 ml in PBS and
subsequently blocked with 1% fatty acid-free BSA in PBS, 1 h at
room temperature. 30610
6 cells were serum starved for 1 h at
37uC, then allowed to adhere to fibronectin-coated dishes for 1 h
at 37uC, or maintained in suspension.
For subcellular fractionation, after washing, cells were pelleted
by centrifugation (5 min, 100 g) and resuspended in a hypotonic
buffer [10 mM HEPES (pH 7.2), 10 mM KCl, 1.5 mM MgCl2,
0.1 mM EGTA, 20 mM NaF, 100 mMN a 3VO4,1 0 mg/ml
aprotinin, 10 mg/ml leupeptin and 1 mM PMSF (Phenylmetha-
nesulfonyl fluoride)] for 30 minutes at 4uC, with shaking. Cells
were broken up using a Dounce homogenizer (90 strokes), after
which the nuclei were pelleted by centrifugation (10 min, 1100 g,
4uC). The nuclei-free supernatant was subjected to a second
13500 g centrifugation for 45 min at 4uC to separate the
membranes from the cytosolic fractions. The membrane pellets
were resuspended in lysis buffer [10 nM Tris-HCl (pH 7.5),
150 mM NaCl, 5 mM EDTA, and 1% Triton X-100] and
sonicated 1 minute. 50 mg of total cytosolic and membrane pellet
proteins were analysed by Western blotting.
For immunoprecipitation of a5 integrin, at the end of adhesion,
cells were washed in PBS and lysed in a buffer containing 20 mM
Tris HCl pH 8, 130 mM NaCl, 1% Triton X-100, 10% glycerol,
orthovanadate and protease inhibitors. After sonication and
centrifugation at 13500 g, supernatant was processed for protein
quantification, preclearing and incubation overnight with 20 mL
a5 polyclonal antibodies. Then, immunoprecipitates were recov-
ered with protein A sepharose, washed and analysed by Western
blotting.
Statistical analysis
Student’s t test was used for statistical analysis of n independent
experiments realized in vitro.
Results
GSK3b, a4b1 and a5b1 integrins are implicated in cell
survival of serum-starved adherent leukemic cells
We have previously demonstrated that a4b1 and a5b1 integrins,
and the kinase GSK3b, regulate the chemosensitivity of adherent
leukemic cells onto fibronectin [8]. Using a siRNA approach, we
show that survival of adherent U937 on fibronectin in serum-
starved conditions involves both GSK3b and b1 integrins (a4b1
and a5b1) (Fig. 1A). Decreased expression of GSK3b (70610%), of
a5b1 (33610%) and of a4b1 (4765%) was assessed by Western
blotting (Fig. 1B). None of these siRNA altered the adhesive
capacities of leukemic cells (Fig. 1B). Viable cell recovery 24 hours
after adhesion assay on fibronectin measured by MTT labeling
was increased in adhesion conditions compared to suspension
(Fig. 1A, 1866%, p,0.01). GSK3b and a5b1 siRNA induced a
3065% decrease of cell recovery in adhesion (p,0.001), whereas
a4b1 siRNA was less potent (1865%, p,0.05). No significant
changes occurred in suspension upon treatment with the different
siRNAs. Of note, identical results were obtained with two sources
of siRNA targeting different sequences of a4 and a5 integrin genes
(not shown).
Since MTT measurement could be the result of both cell
survival and proliferation, apoptotic cell death was assessed after
adhesion assay by annexin labeling (Fig. 1A). Whereas MTT
measurement at 24 hours may reflect both apoptotic and necrotic
processes, annexin labeling was realized at 5 hours to check
specifically for the occurrence of apoptosis. A higher level of
apoptosis was detected in U937 electroporated with control siRNA
comparatively to untreated cells (2062% versus #10%). Adhesion
decreased the amount of annexin-positive cells compared to
suspension (2464%, p,0.05). Downregulation of a5b1 or a4b1
expression in adherent U937 induced an increase of apoptotic cells
compared to control siRNA in adhesion (6965% p,0.01 and
4466% p,0.05, respectively). Knockdown of GSK3b expression
increased apoptosis of adherent U937 (8164%, p,0.01).
Apoptosis in suspension was not significantly changed after
treatment with integrin siRNAs.
Using the pharmacological GSK3b inhibitor SB216763 at a
concentration (10 mM) without deleterious quantitative effect on
cell adhesion (Fig. 1B), we have further demonstrated that, as well
as in U937, the GSK3b-dependent survival pathway occurred in
adherent leukemic cells from patients but not in the HL-60 and
KG1 leukemic cell lines (Fig. 1C). Accordingly, the activated form
of GSK3b (dephosphorylated Ser-9 GSK3b) was increased in
adherent U937 and cells from AML patients, but not in adherent
percentage of survival compared to the non-targeting siRNA (SiC) in suspension. Statistical analysis on compared adhesion/suspension controls and
SiC/SiGSK3 or SiC/SiIntegrin in adhesion: *P,0.05, **P,0.01, ***P,0.001. B- The adhesive capacity of siRNA- or SB216763-treated U937 was
measured by colorimetry (left panel, n=3, mean 6 S.E.M.). SiRNA efficacy against GSK3b, a4b1 and a5b1 was checked by Western blot (right panel,
representative of three independent experiments). C- Survival assay (MTT) was performed as described in Material and Methods with the leukemic
cell lines U937, HL-60, KG1 (n=3, mean 6 S.E.M.) and the leukemic cells from patients (n=8, mean 6 S. E. M.: 1 FAB0, 3 FAB1, 1 FAB2, 1 FAB4, 2 FAB5)
after treatment with the GSK3b inhibitor, SB216763 (10 mM). Variations of cell survival in cells treated by SB216763 compared to the untreated cells in
suspension or in adhesion are shown: **P,0.01, ***P,0.001. D- Variations of the Ser-9 phosphorylation of GSK3b upon adhesion on fibronectin of
U937, HL-60, KG1 and AML patient cells (FAB 5) are shown. Representative of three independent experiments.
doi:10.1371/journal.pone.0009807.g001
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cell survival was found in adherent AML cells classified along
different FAB. However the pro-apoptotic response to SB216763
occurred in 50% AML samples of the cohort (n=16: 3 FAB0, 4
FAB1, 2 FAB2, 3 FAB4 and 4 FAB5) and was more pronounced
in AML from myelomonocytic FAB (Fig. 1C). Furthermore, most
of the blasts underwent CAM-DR in vitro and SB216763
abolished it, as previously described [8].
Altogether, these results demonstrate that engagement of a4b1
and a5b1 integrins to fibronectin supports cell survival of serum-
starved adherent leukemic cells, potentially through activation of
GSK3b via its dephosphorylation.
The inhibitory Ser-9 phosphorylation of GSK3b is
differentially regulated by a4b1 and a5b1 integrins
To further demonstrate that GSK3b is involved in a4b1 and
a5b1-mediated prosurvival effect, we used siRNA to knockdown
integrin expression (Fig. 2A). We have studied consequences of the
decrease in expression of each integrin on GSK3b phosphoryla-
Figure 2. GSK3b is differentially regulated by a4b1 and a5b1 integrins in leukemic cells. A- Specificity and efficacy of siRNA integrins were
checked by Western blot. B- Serum-starved U937 were allowed to adhere on fibronectin for 1 h and the Ser-9 phosphorylation state of GSK3b was
compared to cells in suspension after downregulation of a4 and a5 expression by siRNA. SiC=non-targeting siRNA. Right panel shows the mean 6
S.E.M. variations of the P(S9)GSK3b/GSK3b ratio analyzed by densitometry from three independent experiments. C- The phosphorylation state of
GSK3b was studied in suspension or after adhesion of U937 on surfaces coated with fibronectin (Fn, 40 mg/ml), anti-a4 (1 mg/ml) or -a5 (clone P1D6
0.1 mg/ml; clone JBS5 0.2 mg/ml) antibodies in experimental conditions as for B. Adhesive capacities of U937 in each condition of coating were
measured by colorimetry and are shown on right panel. Data are representative of three independent experiments.
doi:10.1371/journal.pone.0009807.g002
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effects on the inhibitory Ser-9 phosphorylation of GSK3b (Fig. 2B).
Ser-9 phosphorylation of GSK3b was decreased (50%617,
p,0.05) upon adhesion to fibronectin compared to suspension
cells. Whereas a5 siRNA abolished the Ser-9 dephosphorylation of
GSK3b in adhered cells, a4 siRNA had no significant effect on
Ser-9 phosphorylation. Conversely, in suspension, none of integrin
siRNA modified significantly Ser-9 phosphorylation of GSK3b.
These results are in favor of GSK3b activation through Ser-9
dephosphorylation after a5b1 engagement onto fibronectin.
Since we have previously shown that adhesion to surfaces
coated with anti-a4 (clone P4G9) or -a5 (clone P1D6) stimulatory
antibodies supported the chemoresistance of U937 cells [8],
we studied GSK3b phosphorylation in U937 adhered (with the
same efficiency) either to fibronectin or to a4 or a5 antibodies
(Fig. 2C). Adhesion of U937 to coated anti-a5 antibodies induced a
decrease of Ser-9 phosphorylation of GSK3b compared to
suspended cells (60%610, p,0.01), thus mimicking the observa-
tions after adhesion of leukemic cells on fibronectin. However,
specific engagement of a4b1 onto coated anti-a4 antibodies did not
Figure 3. a5 integrin, PP2A and GSK3b are co-localized in adherent leukemic cells. A- The Ser-9 phosphorylation of GSK3b was studied by
Western blot in cytosolic (Ct) and membrane (Mb) compartments of U937 in adhesion or in suspension. B- The presence of GSK3b (and its Ser-9
phosphorylated form), PP2A (and its Tyr-307 phosphorylated form), the scaffolding protein RACK1 and the PI 3-kinase regulatory subunit p85 was
checked by Western blot in a5 immunoprecipitates from U937 in suspension (Susp.) or in adhesion (Adh.). The absence of flotillin in a5
immunoprecipitate demonstrates specificity of the interactions between a5 integrin, PP2A and GSK3b. Right panel (input) indicates the amounts of a5
subunit and GSK3b proteins in the total lysates (Total) and in the supernatants (Sup.), before and after immunoprecipitation of a5 respectively. Data
are representative of three independent experiments.
doi:10.1371/journal.pone.0009807.g003
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compared to suspension (10%615). Interestingly, adhesion of
U937 to coated anti-a5 antibody clone JBS5 induced a strong
adhesion without cell spreading by contrast with fibronectin and
clone P1D6 (not shown and [25]) but was not efficient to trigger
GSK3b dephosphorylation (Fig. 2C). Of note, adhesion of U937
on non-specific Ig did not induce changes in phosphorylation of
GSK3b nor in cell survival (not shown and [8]).
Thesedata unraveladifferentialcontrolofSer-9 phosphorylation
of GSK3b by a4b1 and a5b1 integrins, allowing activation of the
enzyme. However, upon adhesion of serum-starved leukemic cells
on fibronectin, a5b1 alone seems to support GSK3b activation.
Involvement of PP2A in a5b1-mediated GSK3b activation
and cell survival
The phosphatase PP2A is a partner of b1 integrins in the control
of cell survival [26] and regulates Ser-9 phosphorylation of
GSK3b [7]. As shown in Fig. 3A, the inhibitory Ser-9
phosphorylation of GSK3b in the cytosolic/membrane fraction
was found to be strongly decreased in adhesion compared to
suspension. Moreover, the active form of GSK3b (Ser-9
dephosphorylated GSK3b) was increased in a5 integrin immuno-
precipitate from adherent U937 comparatively to suspension and
was found associated with PP2A (Fig. 3B). PP2A was poorly
phosphorylated on its inhibitory site (Tyr-307) in a5 immunopre-
cipitate from adherent U937. Interestingly, adhesion of U937 on
fibronectin triggered the association of the scaffolding protein
RACK1 with a5 whereas it decreased the amount of the PI 3-
kinase regulatory subunit p85 associated with the integrin (Fig. 3B).
These data show that GSK3b is co-localized with a5 integrin in a
molecular complex containing phosphatases and kinases poten-
tially implicated in its regulation.
To further demonstrate that PP2A could play a role in GSK3b
activation, we used okadaic acid (OA) to inhibit PP2A [26]. The
inactive phosphorylated forms of PP2A and GSK3b (phosphoTyr-
307 PP2A and phosphoSer-9 GSK3b, respectively) were de-
creased upon adhesion but restored upon treatment with OA
(Fig. 4A) showing that the activation of the two enzymes were
correlated. Of note, under treatment by OA, a decrease of GSK3b
expression was constantly measured (Fig. 4A) suggesting its Ser-9
phosphorylation-dependent proteasomal degradation as demon-
strated previously [27]. The PP2A regulatory subunit B’ (also
called B56 or PR61) is responsible for the function of PP2A in
cytoskeletal stability [28] and Akt regulation [29], potentially
involved in the control of cell survival and GSK3b regulation.
Indeed we have measured a decrease of the active form of Akt
(Threonine 308 phosphorylated Akt) concomitantly with the
activation of PP2A and GSK3b in adherent leukemic cells
(Fig. 4A). As shown in Fig. 4B, a decrease of a5b1 and PP2A-B’
(40%65) expression by siRNA both triggered an increase in Ser-9
phosphorylation of GSK3b suggesting their roles in keeping
GSK3b in an active state. The PP2A inhibitor OA decreased
survival of adherent U937 (35%, p,0.05) to the same extent as
a5b1 knockdown (Fig. 4C). SiRNA directed against the PP2A
regulatory subunit B’ induced a moderate but significative survival
decrease (14%, p,0.05 statistical apparied test) in adhesion
(Fig. 4C). In suspension, leukemic cells were not significantly
affected under these conditions (not shown). An increase of AML
cell survival was measured upon adhesion on fibronectin (27%66)
or a5 antibody (clone P1D6, 46%63) but not a4 antibody (clone
P4G9, 10%67) compared to suspension. This improvement of
AML cell survival upon adhesion was abolished by OA treatment
(Fig. 4C). These results show a role for PP2A in GSK3b activation
and cell survival of adherent leukemic cells.
Altogether, these data show that PP2A is activated in serum-
starved adherent leukemic cells and cooperate with a5b1 integrin
in leukemic cell survival through the regulation of GSK3b.
a5b1 and GSK3b regulate TNFa resistance and both
extrinsic and intrinsic apoptotic pathways in leukemic
cells
We have previously shown that both a5b1 and a4b1 integrins
supported chemoresistance of U937 cells [8]. Since GSK3b
activation is a5b1 integrin-dependent in our conditions and has
been shown to play a specific pro-survival role through the
response to death receptor activation [21], we checked whether a5
and a4 integrins could be differentially involved in TNFa response.
The incubation of U937 with TNFa in serum-starved suspension
conditions induced a 44%63( p ,0.01) decrease in cell survival
(Fig. 5A). Adherent U937 were more resistant to this treatment
since a decrease of 24%64( p ,0.01) of cell survival was measured.
a5 siRNA as well as GSK3b siRNA, but not a4 siRNA, abolished
the adhesion-dependent resistance to TNFa(Fig. 5A).
The GSK3b-dependent TNFa resistance and NF-kB activation
[8] in adherent leukemic cells suggest that both extrinsic and
intrinsic apoptotic pathways could be regulated by a5b1 integrin
engagement. Indeed the treatment of U937 cells with siRNA
directed to a5 or GSK3b induced a cleavage of caspase 8 and an
increase of cytosolic cytochrome C in favor of the activation of
both apoptotic pathways in adherent leukemic cells treated by
TNFa. As a result of both apoptotic pathways, caspase 3 was
cleaved upon this treatment (Fig. 5B). Protection against TNFa
confered by a5-dependent adhesion and activated GSK3b was
confirmed in AML patient (Fig. 5B).
Thus, these data demonstrate that the engagement of a5b1
integrin and GSK3b activation both support resistance to extrinsic
and intrinsic pro-apoptotic pathways of serum-starved adherent
leukemic cells.
Discussion
In this work, we have demonstrated that adhesion to fibronectin
triggers a specific survival signaling pathway in U937 leukemic
cells upon serum starvation. Importantly, this survival pathway
occurs in leukemic blasts from AML patients and supports their
chemoresistance [8]. The survival advantage conferred by
adhesion to serum-starved leukemic cells requires the activation
of GSK3b. A signaling cascade involving the a5b1 integrin and the
phosphatase PP2A is responsible for Ser-9 dephosphorylation and
thus activation of GSK3b.
Figure 4. a5 integrin and PP2A both regulate GSK3b and survival in leukemic cells. A- Variations of inhibited forms of PP2A (P(Y307)) and
GSK3b (P(S9)), and activated form of Akt (P(T308)), after adhesion of U937 on fibronectin 6 okadaic acid (OA, 100 nM) treatment. B- Consequences of a5
or PP2A-B’ siRNA on Ser-9 phosphorylation of GSK3b were studied. C- Adherent U937 transfected with a5 siRNA or PP2A-B’ siRNA underwent a survival
assay (MTT) in serum-starved conditions as described for Fig. 1. Adhesion of cells from AML patients was performed on fibronectin or on a5 antibody
(P1D6) and a4 antibody (P4G9) as described for Fig. 2 to discriminate the respective implication of both integrins in cell survival measured by APO2.7
labeling in the same conditions as for U937. OA (100 nM) was used to inhibit PP2A in U937 and AML blasts. A, B: Data are representative of three
independent experiments. In C: U937 n=3 (mean 6 S.E.M.), AML patients n=2 (FAB5, mean 6 S.D.), comparison to cells in suspension: *P,0.05.
doi:10.1371/journal.pone.0009807.g004
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PLoS ONE | www.plosone.org 8 March 2010 | Volume 5 | Issue 3 | e9807In adherent conditions, co-localization of GSK3b and PP2A
with a5 integrin in the membrane compartment correlated with
Ser-9 dephosphorylation of GSK3b suggesting the activation of
the enzyme under these conditions. Indeed, inhibition of a5b1 and
PP2A by siRNA or pharmacological drugs induced an increase of
the Ser-9 phosphorylated inhibited form of GSK3b. The b1
Figure 5. a5 integrin and GSK3b regulate the response to TNFa and both extrinsic and intrinsic apoptotic pathways in adherent leukemic
cells. A- U937 transfected with a4,a5or GSK3bsiRNA in suspension or adhesion were treated with TNFa(10 ng/ml) for 4 hours and cell survival assays (MTT)
were performed as described for Fig. 1. Mean 6 S.E.M. n=3,*P,0.05 **P,0.01. Right panel shows the efficacy of siRNA directed to GSK3b, a4 and a5
integrins. B- Extrinsic (caspase-8) and intrinsic (cytochrome C) or both (caspase-3) apoptotic pathways were studied by Western blotting in TNFa-treated
adherent U937 treated with siRNA against a5 or GSK3b. SiC= Sicontrol, representative of three independent experiments. On the right side is shown cell
apoptosis (APO2.7 labeling) measured in TNFa- t r e a t e db l a s t sf r o mA M Lp a t i e n t si ns u s p e n s i o no ri na d h e s i o no nf i b r o n e c t i no ro nP 1 D 6a5 antibody as
described in the legend of Fig. 2 (n=2FAB5,mean6 S.D., *P,0.05). The treatment with the GSK3b inhibitor SB216763 was peformed as described for Fig. 1.
doi:10.1371/journal.pone.0009807.g005
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some integrin heterodimers since it has been demonstrated
downstream of a2b1 [5], a5b1 but not a4b1 engagement.
Moreover, in our experiments, serum starvation was required to
trigger the integrin-dependent GSK3 activation (not shown). The
a5b1/GSK3b pathway supports 30% of survival in adherent
leukemic cells. Interestingly, we have previously implicated this
survival pathway in cell adhesion-mediated drug resistance, where
it was shown to allow a 30% increase in survival [8]. Our data also
demonstrate that the a5b1/GSK3b pathway is involved in TNFa
resistance, caspase 8 and cytochrome C regulation, and activation
of the transcriptional factor NF-kB [8]. Thus, a5b1-mediated
activation of GSK3b modulates both extrinsic and intrinsic
apoptosis signaling pathways [15].
The a5b1/GSK3b pathway could modulate diverse signaling
pathways controlling cell survival. ERK activation has been
described to control cell survival that is linked to integrin
engagement upon serum starvation [30] or Fas stimulation [26].
Moreover, GSK3b regulates MEKK1 demonstrating its implica-
tion in the stress-activated protein kinase pathway [31]. In our
experiments, ERK or p38 inhibition did not influence cell survival
(not shown). Interestingly, the activity of c-Jun N-terminal kinase
(JNK), which is found constitutively activated in most patients with
acute myeloid leukemia, has been correlated with a «multidrug»
anthracycline resistance [32] and controls fibronectin survival
signaling under serum-starvation conditions [33]. Our preliminary
data suggest that JNK is activated in adherent U937. It remains to
determine whether, in our experimental model, JNK activation is
modulated by GSK3b.
Our data show that adhesion of U937 on fibronectin triggers
the association of the scaffolding protein RACK1 with a5b1.
Interestingly, RACK1 has been described as a signal integrator
between growth factor receptor and b1 integrin [34]. PP2A and
the PI 3-kinase regulatory subunit p85 are among the proteins
whose recruitment and dissociation are modulated by RACK1. In
our experiments, both an increase of activated GSK3b and a
decrease of p85 were observed in a5 immunoprecipitate from
adherent U937. This result suggests that the integrin-dependent
activation of GSK3b could result from both increased PP2A and
decreased PI 3-kinase/Akt activities [5]. Accordingly we measured
a concomitant decrease of the active form of Akt with GSK3b
activation in adherent leukemic cells. Thus, survival of U937 in
starved conditions may be linked to a quiescence status with
decreased proliferative and migration capacities [35]. However,
the organization of the cytoskeleton seems to play a key role for the
a5b1-dependent activation of GSK3b since adhesion through the
a5b1 antibody clone JBS5 impaired specifically cell spreading and
did not trigger GSK3b activation. Whether RACK1 directly
regulates PP2A activity or targets GSK3b and PP2A catalytic/
regulatory subunits to specific locations is an open question.
Interestingly, it has been shown that RACK1 is a component of
the signaling pathway of the p55 TNF receptor [36] and is
implicated in the resistance to apoptotic stimuli in hematopoietic
cells [37]. Thus, RACK1 could regulate the death-antagonizing
complex involving GSK3b at TNF receptor [21].
We have previously shown [8] that engagement of both a5b1
and a4b1 supported cell-adhesion mediated drug resistance of
U937. However, a5b1 alone was shown to activate GSK3b and
TNFa resistance. Our unpublished data demonstrate that a4b1
integrin controls U937 survival in adhesion through the tyrosine
kinase Pyk2 activation. It suggests that a5b1/GSK3b and a4b1/
Pyk2-dependent pro-survival pathways could cooperate through
the activation of specific pathways of resistance to extrinsic and
intrinsic pro-apoptotic pathways. Interestingly, our preliminary
data show that the a4b1/Pyk2 cell survival pathway in adherent
U937 involves PI 3-kinase activation and Bcl-xL expression. Since
we have shown that the GSK3b-dependent survival pathway
occurred in U937 but not in HL-60 and KG1 cell lines, it could be
interesting to compare their a5 or a4-dependent adhesive
capacities. Notably, and by contrast with U937, RACK1 increase
and PI 3-kinase subunit p85 decrease were not observed in a5
immunoprecipitates from adherent HL-60 (not shown). However,
we demonstrate that AML cells from patients classified along
different FAB trigger mostly the GSK3b-dependent survival
pathway upon adhesion onto fibronectin. Except a myelomono-
cytic phenotype, this survival pathway was not correlated with
other clinico-biological parameters in patients.
In conclusion, we propose GSK3b activation as a new
adhesion-dependent cell survival pathway that is regulated by
the engagement of specific integrin heterodimers. It could control
a pro-survival response to death receptors but also intrinsic pro-
survival pathways under stress conditions. Importantly, the pro-
survival GSK3b-dependent pathway may represent a new
therapeutic target in cancer cells whose resistance to therapy is
supported by cell adhesion.
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